abstract |
A composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the following structure:n nor a pharmaceutically acceptable salt or hydrate thereof, and a Pharmaceutical acceptable carrier or diluent, for use in the treatment of brain cancer in a mammal, wherein the composition is formulated for oral administration. |